Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Wyeth | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Wyeth

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Wyeth

2Q Revenues: $5.6 billion (+10%)

2Q Earnings: $1.2 billion (+13%)

YTD Revenues: $11 billion (+10%)

YTD Earnings: $2.5 billion (+12%)

Comments: Pharmaceutical sales were $4.7 billion in the quarter, up 11%, driven by higher sales of Prevnar (+22%), Protonix (+25%), Enbrel (+37%), Nutrition products (+19%), and Zosyn (+17%). This increase was offset by lower sales of Zoton and Inderal LA due to generic competition. In the quarter, Lybrel and Torisel received FDA approval. 2Q results include charges of $49.8 million related to the company’s productivity initiatives.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters